

PHARMA MONTHLY

OCTOBER 2026

Key News for the Month

Company

- Novo Nordisk, Eli Lilly set to take obesity drug battle to India
- Lupin launches fixed-dose triple combination inhaler for COPD in India
- Hospital pricing part of wider value chain: Max MD
- FSSAI pulls up Dr. Reddy's, Nestle Health Science over Celevida claims
- I-T dept moves appellate tribunal against Rs32.66cr tax relief to Dr. Lal PathLabs
- Dr. Reddy's Laboratories receives two observations for Andhra Pradesh facility
- Zydus and Formycon: FYB206 becomes first publicly announced Keytruda biosimilar accepted for review by USFDA
- Zydus moves closer to US market for Keytruda biosimilar as FDA accepts application
- Biocon clears path for cancer drug launch
- Biocon settles US patent dispute with Roche's Genentech, eyes 2027 Perjeta biosimilar launch
- Natco Pharma subsidiary launches Carboplatin in US market to address shortages
- Sanofi healthcare receives CDSCO approval for Qftilia therapy for haemophilia patients in India
- Dr Reddy's gets DCGI nod for Zytorvi in advanced esophageal cancer
- Bharat Biotech slashes price of malaria vaccine MOSQIVAC by 40%
- Dr Reddy's rolls out new generic Ozempic brands amid Obeda supply disruption
- Jubilant Pharmova eyes USD150mn through rupee debt sale, bankers say
- Cipla subsidiary clears USFDA inspection with zero observations
- Dr. Reddy's bets on generic semaglutide, biosimilars
- Cipla expects US business to draw support from upcoming product pipeline
- Cipla sets sights on first-wave gains from rollout of Keytruda Biosimilar
- Piramal Pharma cutting China exposure to manage supply-chain resilience: Nandini Piramal
- Sun Pharma ordered to halt eye drug production at Assam plant over quality lapses: Report
- Max Healthcare to add 209 beds with Rs415cr capex
- Alkem Labs clears USFDA inspection at Taloja Unit
- Vimta Labs incorporates WoS in the US
- USFDA approves supplemental Biologics License Application for Ilumya: Sun Pharma

Industry

- Centre may seek legal view on licensing of sterile drugs
- GLP-1 boom in China, India, Brazil could create USD22bn market by 2035: J.P. Morgan
- India's pharma exports rise 4.9% to USD16.14bn in H1; shipments to Europe up nearly 10%: Pharmexcil
- Cancer drug prices fell in 2019 too, but mark-ups of up to 700% are back

Global

- Roche calls for global healthcare overhaul to tackle disease burden
- Johnson & Johnson's prostate cancer drug shrinks tumors in early-stage trial
- Bayer wins Roundup weedkiller cancer trial while awaiting settlement ruling
- USFDA approves Inovio's treatment for rare throat disease; shares surge

Final ANDA Approvals

Company	API	Strengths	Indications	Brand (Company)	Mkt Size
Lupin	Phytonadione Injectable Emulsion	1mg/0.5mL Single-dose Prefilled Syringe	Indicated for treatment and prophylaxis of hypoprothrombinemia	Phytonadione Injectable Emulsion (International Medication Systems Ltd)	USD52.3mn (annual sales Aug 2026)
Zydus Lifesciences	Estradiol and Levonorgestrel Transdermal System	0.045mg/0.015mg per day	Used to treat moderate to severe symptoms of menopause	Climara Pro Transdermal System	USD45.7mn (annual sales Aug 2026)
Alembic Pharma	Venetoclax Tablets	10/50/100mg	Indicated for treatment of adult patients with chronic lymphocytic leukemia	Venclexta Tablets (AbbVie)	USD1584mn
Alembic Pharma	Valganciclovir for Oral Solution	50mg/mL	Indicated for treatment of cytomegalovirus (CMV) retinitis	Valcyte (CHEPLAPHARM)	-
Alembic Pharma	Ciprofloxacin and Dexamethasone Otic Suspension	0.3%/0.1%	Indicated for treatment of infections caused by susceptible isolates of the designated microorganisms	Ciprodex Otic Suspension (Sandoz Inc.)	-

Source: Media Reports and Company Press Releases

BSE Health Care Index Price Performance				
Companies	Price (Rs)	Change		
		1M	6M	12M
3B BlackBio Dx Ltd	1296	-23.4%	4.2%	-3.6%
Aarti Drugs Ltd	436	1.2%	14.2%	-13.2%
Aarti Pharmalabs Ltd	874	-8.3%	35.2%	4.6%
Abbott India Ltd	25593	-5.7%	-4.8%	-13.6%
Acutaas Chemicals Ltd	4003	22.1%	27.6%	134.6%
Advanced Enzyme Technologies Ltd	263	-6.3%	-27.8%	-15.6%
Ajanta Pharma Ltd	3512	-2.9%	20.7%	42.3%
Akums Drugs and Pharmaceutical Ltd	732	-10.6%	39.8%	57.0%
Alembic Pharmaceuticals Ltd	798	-3.4%	8.5%	-11.4%
Alivus Lifesciences Ltd	1408	2.1%	33.2%	54.7%
Alkem Laboratories Ltd	5125	-0.4%	-6.8%	-7.2%
Anuh Pharma Ltd	87	-0.7%	13.3%	-2.4%
Apollo Hospitals Enterprise Ltd	8400	3.2%	2.7%	7.9%
Artemis Medicare Services Ltd	292	-15.5%	6.4%	16.0%
Aster DM Healthcare Ltd	683	-1.8%	-6.3%	-2.2%
AstraZeneca Pharma India	6367	2.9%	-26.6%	-32.7%
Aurobindo Pharma Ltd	1678	0.7%	17.3%	52.2%
Bajaj Healthcare Ltd	306	-6.2%	1.5%	-36.3%
Biocon Ltd	352	-5.12%	-17.8%	-6.6%
Bliss GVS Pharma Ltd	648	-6.8%	52.6%	315.0%
Blue Jet Healthcare Ltd	504	-6.4%	11.1%	-22.2%
Caplin Point Laboratories Ltd	2325	-14.2%	14.52%	14.5%
Cipla Ltd	1380	2.2%	-1.3%	-10.4%
Cohance Lifesciences Ltd	444	0.1%	3.7%	-42.7%
Concord Biotech Ltd	1245	-9.3%	18.4%	-14.3%
Dishman Carbogen Amics Ltd	145	-7.5%	-25.8%	-50.7%
Divi's Laboratories Ltd	9715	4.7%	45.9%	46.0%
Dr. Agarwal's Health Care Ltd	508	5.94%	4.9%	-2.1%
Dr. Lal PathLabs Ltd	1906	-4.1%	19.2%	23.4%
Dr. Agarwals Eye Hospital Ltd	5280	3.05%	6.2%	2.1%

Source: BSE website; All prices are as on 30th Oct, 2026

BSE Health Care Index Price Performance				
Companies	Price (Rs)	Change		
		1M	6M	12M
Dr. Reddy's Laboratories Ltd	1350	9.2%	3.6%	12.3%
Emcure Pharmaceuticals Ltd	1868	-3.8%	9.6%	40.1%
Eris Lifesciences Ltd	1160	-2.6%	-16.2%	-28.6%
FDC Ltd	377	10.9%	-6.7%	-16.7%
Fermenta Biotech Ltd	418	-24.03%	41.4%	55.7%
Fischer Medical Ventures Ltd	25	-26.1%	-35.1%	-78.9%
Fortis Healthcare Ltd	770	0.2%	-17.2%	-26.2%
Gland Pharma Ltd	3098	6.7%	37.7%	62.0%
GSK Pharmaceuticals Ltd	2484	-10.3%	12.4%	-5.2%
Glenmark Pharmaceuticals Ltd	2308	-0.1%	1.5%	22.5%
Global Health Ltd	1269	-7.0%	7.3%	-7.3%
GPT Healthcare Ltd	133	-12.0%	-6.8%	-11.1%
Granules India Ltd	840	-0.9%	8.7%	46.1%
Gufic Biosciences Ltd	412	-4.5%	23.1%	27.3%
Gujarat Themis Biosyn Ltd	363	-6.5%	-10.3%	-22.4%
HealthCare Global Enterprises Ltd	585	-12.2%	-8.1%	-24.7%
Hester Biosciences Ltd	2300	5.8%	14.9%	43.7%
Hikal Ltd	211	-3.1%	7.5%	-12.2%
Indegene Ltd	588	-0.4%	15.6%	6.6%
Indoco Remedies Ltd	208	-20.8%	-0.6%	-25.6%
Indraprastha Medical Corp. Ltd	305	-12.6%	-19.8%	-48.3%
Innova Captab Ltd	1031	-10.97%	21.0%	24.0%
IOL Chemicals and Pharma Ltd	178	-14.2%	38.1%	90.4%
IPCA Laboratories Ltd	1928	0.02%	27.4%	49.6%
Jagsonpal Pharmaceuticals Ltd	217	-8.5%	5.1%	-1.5%
Jubilant Pharmova Sciences Ltd	925	-10.1%	-6.9%	-17.4%
Jupiter Life Line Hospitals Ltd	256	1.1%	-3.9%	-19.7%
KMC Speciality Hospitals Ltd	149	-13.4%	47.7%	112.1%
Kopran Ltd	239	-14.0%	16.0%	44.4%
Kovai Medical Center & Hospital Ltd	5808	-3.4%	8.4%	-12.0%

Source: BSE website; All prices are as on 30th Oct, 2026

BSE Health Care Index Price Performance				
Companies	Price (Rs)	Change		
		1M	6M	12M
KIMS Ltd	702	-6.2%	-7.4%	-3.8%
Krsnaa Diagnostics Ltd	504	-9.9%	-6.6%	-35.4%
Kwality Pharmaceuticals Ltd	3474	-4.5%	50.3%	287.6%
Laurus Labs Ltd	2392	20.7%	73.9%	146.6%
Laxmi Dental Ltd	178	-7.18%	-24.1%	-44.1%
Lincoln Pharmaceuticals Ltd	502	-14.2%	-20.6%	-6.0%
Lupin Ltd	2009	-1.62%	-11.6%	3.3%
Mankind Pharma Ltd	2489	-0.6%	3.2%	1.8%
Marksans Pharma Ltd	307	-4.8%	24.6%	67.1%
Max Healthcare Institute Ltd	860	-7.5%	-10.8%	-26.8%
Metropolis Healthcare Ltd	545	0.6%	-0.1%	10.8%
Morepen Laboratories Ltd	114	-9.8%	162.5%	135.6%
Narayana Hrudayalaya Ltd	1720	-4.1%	-9.4%	-4.1%
Natco Pharma Ltd	783	-5.4%	-23.0%	-6.1%
Nectar Lifesciences Ltd	10	-0.6%	-17.2%	-35.2%
Neuland Laboratories Ltd	19701	-7.9%	15.4%	21.8%
Novartis India Ltd	1694	-12.0%	8.9%	96.4%
Onesource Specialty Pharma Ltd	1563	2.5%	-12.1%	-14.9%
Orchid Pharma Ltd	833	-16.3%	5.4%	17.5%
Panacea Biotec Ltd	313	-14.4%	-24.1%	-29.2%
Pfizer (India) Ltd	3687	-4.9%	-19.8%	-30.5%
Piramal Pharma Ltd	239	15.9%	38.7%	18.0%
Poly Medicure Ltd	1448	-13.6%	7.4%	-26.7%
Procter & Gamble Health Ltd	5697	2.0%	-5.8%	-7.8%
Rainbow Children's Medicare Ltd	1218	-7.4%	-12.1%	-11.8%
RPG Life Sciences Ltd	2572	-15.3%	16.5%	5.6%
Sai Life Sciences Ltd	1560	2.2%	34.6%	69.4%
Sanofi Consumer Healthcare India Ltd	3435	-9.76%	-25.2%	-26.0%
Sanofi India Ltd	3204	4.8%	3.1%	-33.4%
Sastasundar Ventures Ltd	273	-3.4%	-10.5%	-9.0%

Source: BSE website; All prices are as on 30th Oct, 2026


BSE Health Care Index Price Performance				
Companies	Price (Rs)	Change		
		1M	6M	12M
Senores Pharmaceuticals Ltd	1134	-18.1%	1.3%	46.0%
Sequent Scientific Ltd	219	-7.4%	-15.7%	2.4%
Shalby Ltd	121	-13.1%	-28.8%	-49.9%
Shilpa Medicare Ltd	955	-8.7%	91.6%	164.5%
Shree Ganesh Remedies Ltd	617	-10.1%	-5.1%	23.4%
Sigachi Industries Ltd	26	-8.5%	24.0%	-28.3%
SMS Pharmaceuticals Ltd	512	7.1%	38.4%	77.3%
Solara Active Pharma Sciences Ltd	633	-12.7%	19.9%	4.6%
Strides Pharma Science Ltd	1069	-4.4%	-3.6%	25.8%
SPARC Ltd	177	-10.3%	-16.5%	29.1%
Sun Pharmaceutical Industries Ltd	1778	-2.3%	-1.2%	4.4%
Supriya Lifescience Ltd	846	-11.0%	-12.6%	12.3%
Suraksha Diagnostic Ltd	317	-10.7%	11.37%	-1.7%
Suven Life Sciences Ltd	258	-19.3%	-7.6%	33.9%
Snycom Formulations (India) Ltd	19	-23.7%	28.1%	15.4%
Syngene International Ltd	403	10.4%	-8.7%	-38.1%
Tarsons Products Ltd	292	-9.1%	40.9%	1.0%
Themis Medicare Ltd	95	-18.8%	-13.6%	-23.6%
Thyrocare Technologies Ltd	457	-14.5%	-9.8%	-66.1%
Torrent Pharmaceuticals Ltd	4635	-3.5%	5.5%	28.7%
Unichem Laboratories Ltd	483	-11.5%	38.1%	1.9%
Vijaya Diagnostic Centre Ltd	1447	0.8%	10.6%	45.3%
Vimta Labs Ltd	485	-19.6%	3.4%	-32.3%
Wanbury Ltd	190	-4.6%	-37.9%	-26.2%
Windlas Biotech Ltd	877	-20.0%	6.2%	-7.3%
Wockhardt Ltd	1896	-10.4%	-6.6%	46.9%
Yatharth Hospital & Trauma Care Services Ltd	928	-10.2%	16.2%	17.9%
Zydus Lifesciences Ltd	1244	6.9%	15.4%	26.1%

Source: BSE website; All prices are as on 30th Oct, 2026

NIFTY PHARMA COMPANIES					
Company	Price (Rs)	Mcap (Rs mn)	Change		
			1M	6M	12M
Abbott India Ltd	25593	543840	-5.7%	-4.8%	-13.6%
Alkem Laboratories Ltd	5125	612771	-0.4%	-6.8%	-7.2%
Aurobindo Pharma Ltd	1678	965369	0.7%	17.3%	52.2%
Ajanta Pharma Ltd	3512	438906	-2.9%	20.7%	42.3%
Biocon Ltd	352	573652	-5.1%	-17.8%	-6.6%
Cipla Ltd	1380	1114861	2.2%	-1.3%	-10.4%
Divi's Laboratories Ltd	9715	2579027	4.7%	45.9%	46.0%
Dr. Reddy's Laboratories Ltd	1350	1126985	9.2%	3.6%	12.3%
Gland Pharma Ltd	3098	511121	6.7%	37.7%	62.0%
Glenmark Pharmaceuticals Ltd	2308	651375	-0.1%	1.5%	22.5%
Ipca Laboratories Ltd	1928	489066	0.02%	27.4%	49.6%
Laurus Labs Ltd	2392	1292427	20.7%	73.9%	146.6%
Lupin Ltd	2009	918696	-1.6%	-11.6%	3.3%
Piramal Pharma Ltd	239	318259	15.9%	38.7%	18.0%
Mankind Pharma Ltd	2290	945894	-0.6%	3.2%	1.8%
Sun Pharmaceutical Industries Ltd	1778	4266617	-2.3%	-1.26%	4.4%
Sai Life Sciences Ltd	1560	331309	2.2%	34.6%	69.4%
Torrent Pharmaceuticals Ltd	4635	1763062	-3.5%	5.5%	28.7%
Wockhardt Ltd	1896	308101	-10.4%	-6.6%	46.9%
Zydus Lifesciences Ltd	1244	1240895	6.9%	15.4%	26.1%

Source: NSE website, Company Research; All prices are as on 30th Oct, 2026

Nifty Pharma Index Vs. Nifty Index



Source: NSE website

DISCLAIMERS AND DISCLOSURES-

Progressive Share Brokers Pvt. Ltd. and its affiliates are a full-service, brokerage and financing group. Progressive Share Brokers Pvt. Ltd. (PSBPL) along with its affiliates are participants in virtually all securities trading markets in India. PSBPL started its operation on the National Stock Exchange (NSE) in 1996. PSBPL is a corporate trading member of Bombay Stock Exchange Limited (BSE), National Stock Exchange of India Limited (NSE) for its stock broking services and is Depository Participant with Central Depository Services Limited (CDSL) and is a member of Association of Mutual Funds of India (AMFI) for distribution of financial products.

PSBPL is SEBI registered Research Analyst under SEBI (Research Analysts) Regulations, 2014 with SEBI Registration No. INH000000859/Research Analyst BSE Enlistment No. 5049. PSBPL hereby declares that it has not defaulted with any stock exchange nor its activities were suspended by any stock exchange with whom it is registered in last five years. PSBPL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

PSBPL offers research services to clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

Other disclosures by Progressive Share Brokers Pvt. Ltd. (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company (s) covered in this report-:

· PSBPL or its associates financial interest in the subject company: NO

· Research Analyst (s) or his/her relative's financial interest in the subject company: NO

· PSBPL or its associates and Research Analyst or his/her relative's does not have any material conflict of interest in the subject company. The research Analyst or research entity (PSBPL) has not been engaged in market making activity for the subject company.

· PSBPL or its associates actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· Research Analyst or his/her relatives have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of publication of Research Report: NO

· PSBPL or its associates may have received any compensation including for brokerage services from the subject company in the past 12 months. PSBPL or its associates may have received compensation for products or services other than brokerage services from the subject company in the past 12 months. PSBPL or its associates have not received any compensation or other benefits from the Subject Company or third party in connection with the research report. Subject Company may have been client of PSBPL or its associates during twelve months preceding the date of distribution of the research report and PSBPL may have co-managed public offering of securities for the subject company in the past twelve months.

· The research analyst has served as officer, director or employee of the subject company: NO

· Registration granted by SEBI and certification from NISM is in no way guarantee performance of the intermediary or provide any assurance of returns to investors

PSBPL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. Our sales people, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses (if any) may make investment decisions that may be inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution publication, availability or use would be contrary to law or regulation or which would subject PSBPL or its group companies to any registration or licensing requirement within such jurisdiction. If this document is sent or has reached any individual in such country, especially, USA, the same may be ignored. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of PSBPL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of PSBPL or its Group Companies. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

Terms & Conditions:

This report has been prepared by PSBPL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of PSBPL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and its at discretion of the clients to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. PSBPL will not treat recipients as customers by virtue of their receiving this report.

Registered Office Address:

Progressive Share Brokers Pvt. Ltd,

122-124, Laxmi Plaza, Laxmi Indl Estate,

New Link Rd, Andheri West,

Mumbai-400053, Maharashtra

www.progressiveshares.com | Contact No.:022-40777500

Compliance Officer:

Ms. Mamatha Poojari,

Email: compliance@progressiveshares.com,

Contact No.:022-40777500

Grievance Officer:
Email: grievancecell@progressiveshares.com